Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder

Completed · Phase 4

Conditions studied: Social Anxiety Disorder

In brief

The main purpose of this study is to determine how safe and effective Gabitril is for outpatients with Social Anxiety Disorder (SAD).

Key facts

Study ID

NCT00208741

Run by

Emory University

People needed

50

Starts

2002-06-01

Expected to finish

2003-11-01

Last updated by the study team

2013-11-11

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary diagnosis of SAD
• CGI (S) ≥ 4 at screen
• LSAS ≥ 50 at baseline
• Covi Anxiety Scale score greater than the Raskin depression Scale total score at screen

You may not qualify if…

• Non-responsive to adequate trials of two or more treatment medications, if previously treated for SAD.
• HAM-D ≥15 or a score of >2 on Item 1 at baseline
• Serious or unstable medical condition
• Alcohol or substance use disorder within 6 months prior to study

Where it is running

• Emory University School of Medicine — Atlanta, Georgia, United States
• Hillside Hospital of the North Shore-Long Island Jewish Health System — Long Island City, New York, United States
• Columbia/New York State Psychiatric Institute — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.